Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex pleomorphic adenoma

Expert Opinion on Investigational Drugs

Volumn 19, Issue SUPPL. 1, 2010, Pages

  Yang, Sen ^a,b   Wang, Hong Ping ^b   Wang, Xiao Yi ^b   Guo, Li Juan ^a,b   Tang, Xiu Fa ^b   Gao, Qi Hong ^b   Xuan, Ming ^b   Loo, Wings T Y ^c,d   Chow, Louis W C ^c,d  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIMED Medical Institute   (Hong Kong)

^d Organisation for Oncology and Translational Research   (Hong Kong)

Author keywords

Carcinoma in pleomorphic adenoma; CD44v6; Parotid pleomorphic adenoma; Recurrence

Indexed keywords

CD44V6 ANTIGEN;

ADOLESCENT; ADULT; AGED; CANCER RECURRENCE; CARCINOGENESIS; CARCINOMA EX PLEOMORPHIC ADENOMA; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PAROTID GLAND; PAROTID GLAND CANCER; PAROTID GLAND CARCINOMA; PAROTID PLEOMORPHIC ADENOMA; PAROTIDECTOMY; PROGNOSIS; RISK FACTOR; SCHOOL CHILD;

ADENOMA, PLEOMORPHIC; ADOLESCENT; ADULT; AGED; ANTIGENS, CD44; CARCINOMA; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAROTID NEOPLASMS; YOUNG ADULT;

EID: 77950670256     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003718866     Document Type: Conference Paper

References (26)

1. Palacios E, Valvassori G. Parotid mass: pleomorphic adenoma(mixed tumour). Ear Nose Throat J 1999;78:746-747
2. Junquera L, Alonso D, Sampedro A, et al. Pleomorphic adenoma of the salivary glands: prospective clinicopathologic and flow cytometric study. Head Neck 1999;21:652-656
3. Hou ZY, Wu LG, Yin K. Statistical analysis of 1878 salivary gland tumors according to new WHO classification [in Chinese]. J Mod Stomatol 1999;18:119-122
4. Duck SW, McConnel FM. Malignant degeneration of pleomorphic adenoma clinical implications. Am J Otolarygol 1993;14:175-178
5. Yusumoto M, Sunaba K, Shibuya H, et al. Recurrent pleomorphic adenoma of the head and neck. Neuroradiol 1999;41:300-304
6. Qiu WL, Zhang ZK, Wang DZ. Oral and maxillofacial surgery theory and practice. Beijing: People's Health Press; 1998
7. Phillips PP, Olsen KD. Recurrent pleomorphic adenoma of the parotid gland: report of 126 cases and a review of the literature. Ann Otol Rhinol Laryngol 1995;104:100-104
8. Stennert E, Wittekindt C, Klussmsnn JP, et al. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope 2004;114:158-163
9. Henriksson G, Westrin KM, Carlsoo B, et al. Recurrent primary pleomorphic adenomas of salivay gland origin intrasurgical rupture, histopathologic features, and pseudopodia. Cancer 1998;82:617-620
10. Valentini V, Fabiani F, Perugini M, et al. Surgical techniques in the treatment of pleomorphic adenoma of the parotid gland: our experience and review of literature. J Craniofac Surg 2001;12:565-568
11. Lu WR, Fang YP, Ping JL. The relationship between capsule status and clinic of the pleomorphic adenoma of parotid gland [in Chinese]. Stomatology 1999;19:41-42
12. Okamoto H, Tsuruta Y, Miyahara H, et al. Flow cytometric analysis of proliferative activity of pleomorphic adenoma of salivary gland. Nippon Jibiinkoka Gakkai Kaiho 1998;101:849-855
13. Zhu S, Wang X, Shao L, et al. Flow cytometric analysis of DNA content in parotid tumour and its contiguous acini. J Tongji Med Univ 2000;20:86-88
14. Wen Y, Chen R, Wang C. The pathologic basis of partial parotidectomy in parotid pleomorphic adenoma treatment. Hua Xi Kou Qiang Yi Xue Za Zhi 2003;21:359-360
15. Heider KH, Sproll M, Susani S, et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996;43:245-253
16. Sandstrom K, Nestor M, Ekberg T, et al Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinica characterization of an 111In-labeled monoclonal antibody. Tumour Biol 2008;29:137-144
17. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24
18. Chaiyarit P, Kafrawy AH, Miles DA, et al. Oral lichen planus: an immunohistochemical study of heat shock proteins (HSPs) and cytokeratins (CKs) and a unifying hypothesis of pathogenesis. J Oral Pathol Med 1999;28:210-215
19. Joo M, Lee HK, Kang YK. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis. Anticancer Res 2003;23:1581-1588
20. Ayhan A, Tok EC, Bildirici I, et al. Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecol Oncol 2001;80:355-358
21. Tamiolakis D, Kotini A, Cheva A, et al. Gains and losses of glycoprotein CD44 and secretory component expression in endometrial hyperplasia and neoplasia. Eur Gynaecol Oncol 2002;23:453-456 (Pubitemid 35364679)
22. Wu SB, Shi GS, Lu J. The expression and significance of CD44V6 in oral squamous cell carcinoma and the process of carcinogenesis [in Chinese]. Stomatology 2001;21:65-66
23. Bahar R, Kunishi M, Kayada Y, et al. CD44 variant 6 (CD44v6) expression as a progression marker in benign, premalignant and malignant oral epithelial tissues. Int J Oral Maxillofac Surg 1997;26:443-446
24. Franchi A, Moroni M, Paglierani M, et al. Expression of CD44 standard and variant isoforms in parotid gland and parotid gland tumours. J Oral Pathol Med 2001;30:564-568
25. Yuan RT, Ji XR, Sun XL, et al. The expression of CD44v6 in pleomorphic adenoma and its malignant transformation [in Chinese]. J Mod Stomatol 2001;15:420-422
26. Qin RH, Cheng B, Chen XH, Li RY. Pathological significance and technique for detection of CD44v6 expression in salivary gland tumours [in Chinese]. Acad J Sun Yat-Sen Univ Med Sci 2000;21:316-317